Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organisation (CDMO), has reported a robust financial performance for the fourth quarter and full year ended March 31, 2026, driven by strong growth in its core CDMO business and improved operational efficiencies.
Q4 FY26: Profitability Outpaces Revenue Growth
Akums posted an operating revenue of ₹1,158 crore in Q4 FY26, marking a 9.7% year-on-year increase from ₹1,056 crore in the same quarter last year. The company delivered a sharp improvement in profitability, with adjusted EBITDA rising 61.6% to ₹152 crore compared to ₹94 crore in Q4 FY25. EBITDA margins expanded significantly to 13.1% from 8.9%.
Adjusted profit after tax (PAT) more than doubled to ₹83 crore from ₹35 crore, reflecting a 135% year-on-year growth. PAT margin improved to 7.0% from 3.3% in the corresponding quarter.
FY26 Performance: Steady Growth Across Metrics
For the full year FY26, Akums reported operating revenue of ₹4,359 crore, up 5.9% from ₹4,118 crore in FY25. Adjusted EBITDA grew 13.3% year-on-year to ₹522 crore, while adjusted PAT increased 27.3% to ₹276 crore, highlighting sustained improvement in operational performance.
CDMO Segment Drives Growth
The CDMO business remained the primary growth engine during the quarter. Revenue from this segment rose to ₹952 crore in Q4 FY26 from ₹840 crore in Q4 FY25. EBITDA increased 54.9% year-on-year to ₹137 crore, with margins improving to 14.4% from 10.6%, supported by higher capacity utilisation, strong client engagement, and execution focus.
Segment-Wise Performance
- Domestic Branded Formulations: Revenue remained stable at ₹102 crore in Q4 FY26 compared to ₹104 crore in Q4 FY25, with EBITDA steady at ₹22 crore. For FY26, revenue grew 2.9% to ₹446 crore, while EBITDA rose 17.0% to ₹90 crore.
- International Branded Formulations: Q4 revenue declined to ₹36 crore from ₹40 crore year-on-year. Full-year revenue remained flat at ₹143 crore; however, EBITDA increased 32.3% to ₹36 crore.
- Trade Generics: The segment turned EBITDA-positive at ₹1.4 crore in Q4 FY26. Annual EBITDA loss narrowed significantly to ₹10 crore from ₹28 crore in FY25.
- API Business: Continued to face pricing pressures, with Q4 revenue at ₹41 crore versus ₹50 crore in Q4 FY25 and an operating loss of ₹12 crore. FY26 EBITDA loss marginally reduced to ₹40 crore from ₹44 crore in FY25.
Global Expansion and Regulatory Milestones
During FY26, Akums made notable progress in its global expansion strategy. The company initiated its first commercial formulation supply to Europe, secured EU GMP certifications for oral solids and liquids facilities, and received UK MHRA approval for Rivaroxaban. Additionally, its injectable plant received Brazil’s ANVISA approval, and groundwork began for a new pharmaceutical facility in Zambia.
Dividend Announcement
The Board of Directors has recommended a final dividend of ₹1 per equity share (50% of the face value of ₹2) along with a special dividend of ₹2 per equity share (100% of the face value), reflecting confidence in the company’s financial position.
Management Commentary
Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., said, “FY26 has been a year of steady progress for Akums. We delivered healthy growth in revenue and profitability while continuing to build capabilities for the long term. Our regulatory milestones, international developments and strong domestic performance reflect our focus on building Akums as a global pharmaceutical company and a trusted partner for our clients.”
Sandeep Jain, Managing Director, added, “The Q4 FY26 and full year performance showed improvement across key operational parameters. Our CDMO business continued to perform well as we remain focused on better capacity utilisation, cost discipline and future growth. We are working on multiple digitization and automation initiatives, which will deliver long-term value for the organization.”
Financial Snapshot (₹ crore)
- Revenue: Q4 FY26 ₹1,158 | FY26 ₹4,359
- Adjusted EBITDA: Q4 FY26 ₹152 | FY26 ₹522
- Adjusted PAT: Q4 FY26 ₹83 | FY26 ₹276
- EBITDA Margin: Q4 FY26 13.1% | FY26 12.0%
- PAT Margin: Q4 FY26 7.0% | FY26 6.2%
The company continues to focus on cost optimisation, portfolio rationalisation, and operational efficiency to navigate challenges in the API segment while sustaining overall growth momentum.
